Stephen Liu

Stephen Liu outlines the ARROW study design and findings and discusses the impact of pralsetinib on the care of patients with treatment-naïve and previously treated NSCLC positive for a RET fusion (7:20).

Stephen Liu talks through the latest findings from the ARROW trial of pralsetinib for patients with RET fusion-positive advanced non-small-cell lung cancer.

AMG 757, a half-life extended, bispecific T-cell engager immunotherapy directed against DLL3, has demonstrated tolerability and antitumor activity in patients with previously treated small-cell lung cancer in a phase 1 trial.

The COVID-19 Vaccination Advisory Committee of the US National Comprehensive Cancer Network has provided preliminary recommendations for COVID-19 vaccinations in people with cancer.